

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established by Alberta government-sponsored drug programs.

PATIENT INFORMATION				COVERAGE TYPE	
PATIENT LAST NAME	FIRST NAME	INITIAL		<input type="checkbox"/> Alberta Blue Cross <input type="checkbox"/> Alberta Human Services <input type="checkbox"/> Other	
BIRTH DATE (YYYY-MM-DD)	ALBERTA PERSONAL HEALTH NUMBER				
STREET ADDRESS	CITY	PROV	POSTAL CODE	ID/CLIENT/COVERAGE NUMBER	

PRESCRIBER INFORMATION					
PRESCRIBER LAST NAME	FIRST NAME	INITIAL	PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION		
STREET ADDRESS			REGISTRATION NUMBER		
			<input type="checkbox"/> CPSA	<input type="checkbox"/> ACO	
			<input type="checkbox"/> CARNA	<input type="checkbox"/> ADA+C	
CITY, PROVINCE			PHONE	FAX	
POSTAL CODE			FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED		

Please provide the following information for ALL requests

Diagnosis	Indicate drug requested	Dosage and frequency
<input type="checkbox"/> Rheumatoid Arthritis <input type="checkbox"/> Other (specify) _____	<input type="checkbox"/> Riximyo <input type="checkbox"/> Ruxience <input type="checkbox"/> Truxima	

Pre-treatment scores*	Requests for re-treatment after two-dose course	Please provide reason if a switch from a different drug to rituximab is requested
DAS28 Score _____	Date of initial dose of the previous course of therapy _____	<p>Note: Patients will not be permitted to switch back to a previously trialed biologic agent if they were deemed unresponsive to therapy.</p>
Date _____	Response scores 16 to 24 weeks after initial dose of previous course of therapy	
AND	DAS28 Score _____ Date _____	
HAQ Score _____	HAQ Score _____ Date _____	
Date _____	Current scores	
	DAS28 Score _____ Date _____	
	HAQ Score _____ Date _____	

* New requests for patients currently maintained on the requested biologic also require pre-treatment scores. Scores must be provided to the correct number of decimal places. DAS28 should be reported to one decimal place and HAQ should be reported to two decimal places.

Will the patient be maintained on methotrexate in combination with rituximab?
 YES NO (If not, please specify reason) _____

Please provide the following information for all NEW requests

Previous medications/therapies utilized: Dose, duration and response is required for ALL FIVE of the following, or contraindications, if applicable

Methotrexate PO _____

Methotrexate SC or IM _____

Methotrexate with another DMARD other than leflunomide (specify agent) _____

Leflunomide _____

Anti-TNF therapy _____

Additional information relating to request

PRESCRIBER'S SIGNATURE	DATE (YYYY-MM-DD)	Please forward this request to: • Alberta Blue Cross, Clinical Drug Services 10009-108 Street NW, Edmonton, Alberta T5J 3C5 • FAX: 780 498-8384 in Edmonton • 1-877-828-4106 toll free all other areas
------------------------	-------------------	--

ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST